On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Over 8.8?million Indians aged 60 and above currently live with dementia,
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Subscribe To Our Newsletter & Stay Updated
